Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (Q28293505)

1

object named as

Daniel J Drucker

0 references

author name string

Kristin Taylor

3

0 references

David M Kendall

4

0 references

Michael Trautmann

5

0 references

Dongliang Zhuang

6

0 references

Lisa Porter

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7

0 references

language of work or name

English

0 references

publication date

4 October 2008

0 references

published in

The Lancet

0 references

volume

372

0 references

page(s)

1240-50

0 references

issue

9645

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Hyperglycemia and microvascular and macrovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

The burden of treatment failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

A High-performance Liquid Chromatography Method for Hemoglobin A1c

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Immunogenicity of xenopeptide hormone therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961206-4

7 January 2021

10.1016/S0140-6736(08)61206-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1038227

1038227

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference